注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
CytomX Therapeutics Inc是一家专注于临床阶段肿瘤学的生物制药公司。该公司正在基于其Probody技术平台开发一类用于癌症治疗的研究性条件性激活疗法。其Probody技术平台设计用于在肿瘤微环境中有条件地激活抗体药物,同时最小化健康组织和循环中的药物活性。该公司的候选产品包括条件激活抗体药物结合物(ADC)praluzatamab-ravtansine(CX2009,靶向CD166)和CX-2029、靶向CD71,以及Probody免疫检查点抑制剂pacmilimab(CX-072,靶向PD-L1)和BMS-986249(靶向CTLA-4)。在研究性新药(IND)启用研究中,该公司还有两种临床前制剂,一种以EpCAM/Trop-1为靶点的条件激活ADC(CX-2043)和一种以EGFR和CD3为靶点的双特异性抗体(CX-904)为靶点的条件激活T细胞。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Sean A. McCarthy | 55 | 2011 | Chairman & CEO |
W. Michael Kavanaugh | 66 | 2015 | Member of Scientific Advisory Board |
Matthew P. Young | 53 | 2015 | Lead Independent Director |
James R. Meyers | 57 | 2018 | Independent Director |
Louis M. Weiner | 70 | - | Member of Scientific Advisory Board |
Elaine V. Jones | 67 | 2019 | Independent Director |
Halley E. Gilbert | 52 | 2020 | Independent Director |
Charles L. Sentman | - | 2020 | Member of Scientific Advisory Board |
John M. Lambert | 72 | 2020 | Member of Scientific Advisory Board |
Mani Mohindru | 51 | 2020 | Independent Director |
Lisa M. Coussens | - | 2023 | Member of Scientific Advisory Board |
Alan Ashworth | 62 | 2021 | Independent Director |
Christopher M. Overall | - | 2021 | Member of Scientific Advisory Board |
Zhen Su | - | 2024 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核